Abstract:Objective:To evaluate the effect of botulinum neurotoxin A (BoNT/A) on prevention of chronic migraine (CM) in mice and explore the potential mechanism.Methods:Twenty-four male C57BL/6 mice were randomly divided into control group, nitroglycerin (NTG) group, and BoNT/A+NTG group ( n=8). Mice in the latter two groups were intraperitoneally injected with 10 mg/kg NTG on the 1 st, 3 rd, 5 th, 7 th and 9 th d of experiments to establish CM models. Mice in the BoNT/A+NTG group were injected with 0.18 U/100 μL BoNT/A one h before the first injection of NTG. Mice in the control group were injected with the same dose of normal saline. Basal mechanical withdrawal threshold (MWT) and evoked MWT 2 h after NTG in the facial and hindpaw regions on the 1 st, 3 rd, 5 th, 7 th and 9 th d of experiments were evaluated by von Frey filament test. The motor function of mice 2 h after NTG injection was tested by rotarod test on the 1 st, 3 rd, 5 th, 7 th and 9 th d of experiments. On 9 th d of experiments, the mice were sacrified; the calcitonin gene-related peptide (CGRP), synaptosomal-associated protein 25 (SNAP25), glial fibrillary acidic protein (GFAP) and TRP channel protein expressions in the trigeminal ganglia (TG) and trigeminal nucleus caudalis (TNC), and NOD-like receptor protein 3 (NLRP3) inflammatory factor pathway-related protein expressions in TNC were detected by Western blotting; real-time quantitative PCR (RT-qPCR) was used to detect the NLRP3 inflammatory factor pathway-related mRNA expressions in TNC. The CGRP expression in TNC was detected by immunofluorescent staining. Results:(1) As compared with the control group, the NTG group had significantly decreased basal facial MWT on the 7 th and 9 th d of experiments ( P<0.05); as compared with the NTG group, the BoNT/A+NTG group had significantly increased basal facial MWT on the 7 th and 9 th d of experiments ( P<0.05). As compared with the control group, the NTG group had significantly decreased evoked facial MWT on the 5 th and 9 th d of experiments ( P<0.05); as compared with the NTG group, the BoNT/A+NTG group had significantly increased evoked facial MWT on the 5 th and 9 th d of experiments ( P<0.05). As compared with the control group, the NTG group had significantly decreased basal and evoked MWT in the hindpaw regions on the 3 rd, 5 th, 7 th and 9 th d of experiments ( P<0.05); as compared with the NTG group, the BoNT/A+NTG group had significantly increased basal and evoked MWT in the hindpaw regions on the 3 rd, 5 th, 7 th and 9 th d of experiments ( P<0.05). (2) There was no significant difference in running time on rotarod among the three groups ( P>0.05). (3)Western blotting results showed that as compared with those in the control group, the CGRP and SNAP25 protein expressions were significantly increased in TG of the NTG group ( P<0.05); and those in the BoNT/A+NTG group were significantly decreased as compared with those in the NTG group ( P<0.05). As compared with those in the control group, the CGRP and NLRP3 protein expressions were significantly increased in TNC of NTG group ( P<0.05); and those in the BoNT/A+NTG group were significantly decreased as compared with those in the NTG group ( P<0.05). (4)RT-qPCR results showed that as compared with that in the control group, the IL-1β mRNA expression in TNC of the NTG group was significantly increased ( P<0.05), and that in the BoNT/A prevention group was statistically decreased as compared with that in the NTG group ( P<0.05). (5) Immunofluorescent staining results showed that as compared with that in the control group, the CGRP expression in TNC of the NTG group was significantly increased, and that in the BoNT/A+NTG group was significantly decreased as compared with that in the NTG group ( P<0.05). Conclusion:BoNT/A can reduce the SNAP25 expression in TG, reduce the CGRP release in TG and TNC, and prevent CM onset; BoNT/A can regulate NLRP3 level in TNC.

Polyclonal neural cell adhesion molecule antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength

The Impact of Polyclonal Neural Cell Adhesion Molecule Antibody on the Potency of Botulinum Toxin

IGF-1 Antibody Prolongs the Effective Duration Time of Botulinum Toxin in Decreasing Muscle Strength.

The Behavioural Effects and Sept-Hippocampal Cholinergic Activity Changes Caused by Repeated Bont/A Injection on Facial Muscle in Adolescent Mice

Antinociceptive Effect of Botulinum Toxin A Involves Alterations in AMPA Receptor Expression and Glutamate Release in Spinal Dorsal Horn Neurons

Acrylamide inhibits terminal sprouting triggered by botulinum toxin type A in rats

Influence of Injection of Chinese Botulinum Toxin Type A on the Histomorphology and Myosin Heavy Chain Composition of Rat Gastrocnemius Muscles.

Unilateral Whisker Pad Injection of Botulinum Toxin Type a Enhances Spatial Learning in Mice.

None Detectable Retrograde Transport Of Chinese Botulinum Toxin Type A In Mice By Single Intramuscular Injection

Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction

Effect of Insulin-Like Growth Factor 1 Antibody on Motor Endplate Function after Botulinum Toxin Injection

Experimental Study on Vertebral Muscle Atrophy and Relative Gene Expression Induced by Botulinum Toxin A Injection in Rats

The Effect of Different Localizing Techniques in Guiding Botulinum Toxin Injection in the Treatment of Lower Limb Spasticity in Cerebral Palsy Children

A methodology for dynamic evaluation of the biological efficacy of botulinum toxin and its dose-effect relationship

Intramuscular Botulinum Neurotoxin Serotypes E and A Elicit Distinct Effects on SNAP25 Protein Fragments, Muscular Histology, Spread and Neuronal Transport: An Integrated Histology-Based Study in the Rat

Preventive treatment of nitroglycerin-induced chronic migraine by peripheral single injection of Botulinum Neurotoxin A in mice

Acrylamide Inhibits Nerve Sprouting Induced by Botulinum Toxin Type A

Does Microneedle Fractional Radiofrequency System Inactivate Botulinum Toxin Type A?

Beyond neuromuscular activity: botulinum toxin type A exerts direct central action on spinal control of movement

Prolonging the Duration of Masseter Muscle Reduction by Adjusting the Masticatory Movements after the Treatment of Masseter Muscle Hypertrophy with Botulinum Toxin Type A Injection

Comparison of Neurotoxic Potency Between A Novel Chinbotulinumtoxina with Onabotulinumtoxina, Incobotulinumtoxina and Lanbotulinumtoxina in Rats